Summary of Terminalia arjuna
Primary Information, Benefits, Effects, and Important Facts
Terminalia Arjuna (usually simply referred to as Arjuna) is a tree bark that is used medicinally in Ayurveda for the purposes of cardiovascular health pertaining to the heart itself. It has a large variety of bioactives, with the water extract showing promise at improving left ventricle function of the heart without any observable toxicity of side effects when taken at 500mg thrice a day (every 8 hours).
There are numerous human studies conducted on Arjuna bark, although many of them are low in sample size. Nevertheless, the water extract appears to be effective in improving cardiac function in persons who have recently undergone cardiac trauma or injury; Myocardial Infarction is the most commonly researched ailment in this regard. Only one study exists on otherwise healthy persons, but Arjuna showed benefit in improving left ventricle function in an exercise test and the benefits may affect a person regardless of health state.
In animal models, this extract appears to exert protection on cardiac tissue in response to various cardiac insults including beta(2)adrenergic agonists (like ephedrine, although isoproterenol was used in the studies) and catecholamines themselves.
The water extract appears to be effective for improving cardiovascular health, particularly at the level of left ventricle function. The studies in humans are underpowered at this moment in time and only one in healthy humans (preliminary evidence), but all evidence appears to be promising and in the same positive direction. The water extract appears to be quite safe
Other extracts such as ethanolic or acetone, with different bioactives, may not have similar cardioprotective effects (no human trials, but some in vitro evidence suggesting the bioactives are not in these extracts) yet appear to be somewhat cancer protective. Tumor growth in animal models is reduced with either the ethanolic extract or isolated Arjunolic Acid (commonly seen as the main bioactive) as is reduced DNA damage in response to mutagens, and these are attributed to the antioxidative capacity of Arjuna which is comparable to Vitamin C on a per weight basis. Due to the anti-cancer effects of the ethanolic extract having some cytotoxic properties, and LD50 has actually been established with this extract and it is possible that side-effects may occur. Additionally, the anti-cancer evidence is somewhat limited as although cytotoxicity has been established in cancer cells a lack of evidence exists to assess healthy cells (a good anti-cancer drug will be highly selective in killing cancer cells, which Arjuna does, and not healthy cells, which Arjuna has not been sufficiently tested for).
Other possible uses of Arjuna include ulcer protection in the stomach with potency similar to Rantidine in one study (associated with the ethanolic extract), protection to the liver and kidney likely mediated by antioxidative properties (ethanolic extract) and the cardiovascular properties may increase anaerobic cardiovascular performance in healthy persons (with the one study using sprinting as a test) although this last claim has a lone study in support of it and no replication.
Ethanolic extracts have potent antioxidative and potentially potent anticancer effects, but although there are no reported side effects with the ethanolic extracts currently (due to a lack of human interventions) it is theoretically plausible that higher than recommended doses could be harmful related to the anticancer effects (cytotoxicity)
Evidence-based information on what works
No fake reviews. No selling you supplements. Just the science.
Our free supplement mini-course teaches you what works, what's a waste, and how to achieve your health goals.
Join the over 200,000 people who have gone through this course (saving themselves time, money, and stress).
Things To Know & Note
Is a Form Of
Also Known As
Arjuna, Dhavala, Kakubha, Nadisarja, Veeravriksha, Partha, Indradru
Goes Well With
Ashwagandha (appears to benefit cardiovascular function on parameters that Arjuna does not, and combination therapy in health persons has at once been shown to confer additive benefits to exercise capacity with both being effective in isolation)
Caution NoticeExamine.com Medical Disclaimer
The water extract (used for cardiovascular health) and ethanolic/acetone extracts (used for cancer prevention and antioxidant purposes) are markedly different and, for all intents and purposes, should be treated as different supplements
How to Take Terminalia arjuna
Recommended dosage, active amounts, other details
A standard dose for the purposes of cardiac health appears to be 500mg of the bark (water extract) taken daily in the morning without food (no evidence exists to suggest that taking it with food is bad or anything). For persons who suffered cardiac trauma (such as Myocardial Infarction), this dose tends to be taken thrice a day every 8 hours
The leaf extracts and ethanolic extracts appear to be more related to the cytotoxic and anti-tumor effects, but not enough evidence exists to recommend an active dose of these extracts for human consumption.
Get access to the latest nutrition research
By becoming an Examine.com Member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects terminalia arjuna has on your body, and how strong these effects are.
|Grade||Level of Evidence [show legend]|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Minor||- See study|
|Minor||Very High See 2 studies|
|Minor||- See study|
|Minor||- See study|
|Minor||- See study|
|-||- See study|
Get access to the latest research
By becoming an Examine.com Member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Research Breakdown on Terminalia arjuna
Click on any below to expand the corresponding section. Click on to collapse it.
Terminalia arjuna (of the Combretaceae family) is a tree; a deciduous evergreen tree standing up to 20-30m above ground level. The bark of the tree appears to have medicinal properties, mostly touted to be a cardioprotective agent. It has been used in Ayurveda under the names of Arjuna, Dhavala, Kakubha, Kumbuk, Nadisarja, Veeravriksha, Partha, and Indradru. Other notable species in the Terminalia family include bellerica and chebula.
Beyond being used for its cardioprotective/cardiotonic abilities, Arjuna has also been reportedly used for genital health (leucorrhoea, Spermatorrhoea), urinary astringent, expectorant, and some aphrodisiac properties.
Traditional administration of Arjuna involves a decoction made with the bark and milk drank in the morning, or at least the powder of the tree bark; in the cases of fractures or contusions with echymosis, honey tends to be recommended. Usually 1-3g of the bark is used per day.
The tree bark, the main medicinal component, contains:
The triterpenoids Arjunic acid and Arjunolic Acid, up to 3% and 1.5% (respectively) of an Ethyl acetate extract or 2% and 0.9% of a diethyl ester extraction. Minimal quantities (0.2-0.3% of each) in acetone, methanol, and ethanol extracts with a 60:40 ethanol:water extract reaching up to 0.72% and 0.48%, respectively. Arjunic acid has bioactive metabolites as well
Ajunglycosides IV and V in the butanolic/methanolic fractions, also in the fruits of Terminalia chebula
Arjunaphthanoloside, a napthanol glycoside
Ursane triterpenoids (2α,3β-dihydroxyurs-12,18-dien-28-oic acid 28-O-β-D-glucopyranosyl ester )
The three above triterpenoids are commonly seen as the main active ingredients, with other compounds with names related to this plant (Terminoside or Arjunoside as examples) tend to be glycosides of the three above aglycones. That being said, there is no evidence to support that these are the compounds that underlie the cardiovascular health properties although they appear to be causative of anti-cancer and anti-oxidative properties
And the fruits that the tree bears may contain:
Arjunglucoside I-III and Arjunetin
Hydrolyzable tannin structures (Ellagic acid, Gallic acid, Corilagin, Chebulagic acid, etc.)
Chebuloside II and Bellericoside
Total phenolics may reach up to 8.05mg/100g in hydroalcoholic extracts of the bark; tannins may reach 5.1mg/100g.
In vitro, the water extract of Arjuna bark appears to have cardiotonic effects with 50ug/mL having similar potency (assessed via amplitude of CS (cell shortening), indicative of contractility) to 100nM Isoproteronol and 1mM Ouabain. The mechanism appears to be different, as a decrease in the decay time during relaxation was noted with both Isoproterenol and Arjuna (not with Ouabain) and both Arjuna and Ouabain (not Isoproterenol) caused an increase in the rise time during contraction. This was only observed with the water extract, with various organic extractions (ethanolic, ethyl acetate) causing varying effects and isolated Arjulinolic acid being arrhythmogenic (causing arrythmia).
Appears to have cardiotonic effects in vitro with isolated heart cells, seems to be associated with the water extract mostly
One month of treatment of 500mg/kg Arjuna bark extract (50% ethanolic) to normal and diabetic rats, reflex bradycardia (a reduction in heart rate in response to high blood pressure, which attempts to normalize blood pressure) was improved in the diabetic rats; the state of diabetes being known to reduce this reflex. The alterations in reflex tachycardia (an increase in heart rate in response to low blood pressure) were not improved by Arjuna over 30 days. The beneficial effects on baroreflexivity has also been noted in isoproterenol (beta-2-adrenergic agonist; like ephedrine) induced cardiac failure, where Arjuna was able to exert rehabilitative and prophylaxtic protection and reduce both cardiac hypertrophy and fibrosis.
Reflex Bradycardia (Baroreflex) is a mechanism where the heart slows its pulsatile power when blood pressure gets too high, which acts to normalize blood pressure. Arjuna, although the mechanisms are unknown, appears to preserve this reflex in situations where the reflex would be hindered (cardiotoxicity, diabetes). The opposite (reflex tachycardia) may not be influenced
In regards to cardiotoxicity, Arjuna appears to be protective against beta-2-adrenergic agonist induced cardiotoxicity (usually using isoproteronol as a means to induce toxicity) in the range of 100-200mg/kg water or water:ethanolic extracts in rodents; this appears to extend to catecholamine-induced cardiotoxicity as well.
Other studies in animal models have noted cardioprotection against sodium fluoride-induced oxidative stress, the chemotherapeutic Doxorubicin, ischemia-reperfusion, and Carbon tetrafluoride.
Appears to be protective against catecholamine and stimulant-induced cardiotoxicity after oral ingestion to rodents, and protective against other general stressors such as oxidative stress
Specifically looking at human interventions, in persons with myocardial infarction or ischaemic cardiomyopathy given 500mg of the bark extract after operation and for a subsequent 8 weeks in addition to standard therapy (relative to control, recieving only standard therapy of nitrates and aspirin/beta-blockers) noted an increase in left ventricular ejection fraction (12.32% versus 2.52%) and a reduction in left ventrical mass (20% versus no change) only in the Arjuna group without any observable toxicity. Higher doses tend to be used, with thrice daily dosing of Arjuna bark water extracts showing benefit in persons with acute myocardial infarction (AMI) by reducing mitral regurgitations (independent risk factor for mortality in persons with AMI) at 1 month (49%) and 3 months (72%) relative to baseline as assessed by echocardiography, with improvements in diastolic function (E/A ratio) at 1 month (29%) and 3 months (48%). 2 weeks of thrice daily dosing of 500mg Arjuna bark water extract alongside standard therapy noted improvements in left ventricle function including ejection fraction, and end diastolic and systolic volume (11 persons with AMI, 1 person with peripartum cardiomyopathy) and benefit to cardiovascular health remained when an open-label follow-up was conducted for 20-28 months. The study recording mitral regurgitations made note that a placebo group was given, but the placebo and its relations to active control were not elaborated on.
A trial with a larger sample (58 persons with chronic stable angina and provocable ischemia on a treadmill test) using 500mg Arjuna extract thrice daily against 40mg isosorbide mononitrate (vasodilating drug) as active control noted improved performance on a treadmill test (maximal cardiovascular exercise duration and recovery time) as well as cardiac function (maximal ST depression) where Arjuna was comparable to Isosorbide mononitrate.
The thrice daily dosing of 500mg Arjuna water bark extract has also been used in one case study on Beta-Thalassemia where a reduction of Lp(a) from 51.8 to 39mg/dL was recorded; the paper made note of a conference presentation (does not appear to be a publication) where a similar observation was noted.
In regards to human trials on cardiovascular health, a once (but more commonly thrice) daily dosing with even intervals between doses shows benefit to cardiovascular and left ventricle function in persons who have suffered myocardial infarctions, with the benefits appearing to extend to other cardiac conditions (Angina in one trial, Beta-Thalassemia according to a case study). Numerous studies, although many are used alongside standard cardiovascular drug treatment rather than monotherapy and most have small sample sizes and statistical power
In a research model of hypercholesterolemic rabbits the ethanolic extract of Arjuna (100-200mg/kg) over 72 days was able to attenuate the increases in triglycerides, LDL-C, HDL-C, and attenuate the increase in the artherogenic index by 49-80%; when compared to 10mg/kg Atorvastatin, 200mg/kg Arjuna tended to underperform nonsignificantly on all parameters.
Triglyceride lowering effects have been noted in rats in response to Poloxamer 407, with the ethanolic outperforming the ethyl acetate fraction when 175-350mg/kg is taken alongside P-407. P-407 is an experimental tool to assess high triglyceride levels by inhibiting LPL activity and preventing cellular uptake of triglycerides. Another study using chemically induced high triglycerides (triton WR-1339) noted similar effects with only the ethanolic fraction being statistically significant, and was replicated in a diet-induced hypertriglyceridemia model where 250mg/kg of the ethanolic extract over one week.
One study in smokers using Arjuna extracts at 500mg daily for 2 weeks noted that the impaired flow mediated vasodilation (FMD) seen in smokers is somewhat normalized with Arjuna, but not placebo; the authors attributed this to the antioxidative effects of Arjuna, as they are noted also with Vitamin C.
The 50% methanolic extract of the bark of Arjuna appears to be able to inhibit alpha-amylase with an IC50 of 302+/-0.55μg/mL, with the bioactives (currently unknown) possibly existing in the water component as the 100% methanolic extract has less inhibitory potential.
A study using the methanolic leaf extract in streptozotocin-induced diabetic mice noted that 100-200mg/kg bodyweight for 15 days was able to dose-dependently reduce elevated fasting blood glucose, with 100mg/kg attenuating 89% of the increase in blood glucose seen in diabetic control and both 200mg/kg Arjuna as well as the active control of 0.5mg/kg Glibenclamide both normalizing blood glucose. Similar to the potency observed with glucose, both Arjuna at the higher dose and Glibenclamide drastically reduced serum liver enzymes and cholesterol to near control levels.
A study assessing the effects of Arjuna (500mg water extract of the bark) with or without Ashwagandha (500mg water extract of the roots) in normal weight young adults over 8 weeks noted that, relative to placebo, maximal oxygen consumption capacity was increased 4.8% and average maximal power output (assessed by Sprinting and measured by a Kinematic Measuring System) increased 3.6% with a decrease of blood pressure from 123.00+/-2.87mmHg to 117.80+/-1.48mmHg (4.3%). Pairing with Ashwagandha increased the power output to 11.6% with a 10% increase in relative power, and also induced significant improvements in VO2 max and oxygen carrying capacity (both seen with Ashawgandha in isolation).
At least one study has noted improvements in anaerobic cardiovascular exercise performance (high intensity cardio), and the benefits appear to be somewhat additive with Ashwagandha
An ethanolic extract of Arjuna at 21.42mg/kg and 42.84mg/kg in rats (human equivalents of 3.4 and 6.8mg/kg) who were administered thyroxine (T4, a thyroid hormone at 0.5mg/kg for two weeks) noted that the serum increase in T3 and T4 was attenuated by 42% and 79% by administration of Arjuna; the increase in lipid peroxidation of cardiac and liver tissue by T4 was simulatenously abolished. Similar effects were noted in euthyroidic rats, but an increase in hepatic lipid peroxidation occurred. The authors noted that similar effects with the antithyroid drug Propyl thiouracil and hypothesized that Arjuna ethanolic extract has anti-thyroid effects, and due to hyperthyroidism causing cardiac tissue enlargment it is thought this may contribute to the cardioprotective effects observed with Arjuna.
Possible thyroid reducing properties, which need to be replicated with a water soluble extract (and mechanisms explored more). May possibly contribute to cardioprotective effects, although not likely to be the only mechanism (as cardioprotection has been noted in persons with normal thyroid status)
The methanolic extract of Arjuna appears to protect gastric tissue from lipopolysaccharide (LPS) from Heliobactor Pylori, which is known to induce ulcers. This protective effect has been noted against alcohol (7 day preload), Dexamethasone (10 day preload), and diclofenac sodium (single dose) where 100-200mg/kg of an 80% ethanolic extract conferred absolute protection against ulcer formation from Dexamethasone and alcohol, while 400mg/kg of an acute dose conferred absolute protection against Diclofenac Sodium. The positive control in this study, Rantidine (35mg/kg Diclofenac, 50mg/kg alcohol, 4mg/kg Dexamethasone) also conferred absolute protection, and these protective effects against Diclofenac have been replicated with a methanolic extract and thought to be related to the anti-oxidative potential.
One study noted that Arjuna extracts, especially acetonic extraction, was able to cause death of Staphylococcus aureus bacteria and extended to Escherchia Coli, Acinetobacter sp, Proteus mirabilis, and Candida albicans; the authors hypothesized that the results suggest that Arjuna may be useful against ear infections (although admittedly preliminary).
In isolated hepatocytes (HepG2), 5-100mcg/mL of the water extract of Arjuna is able to concentration dependently reduce the biomarkers of oxidation induced by TERT (pro-oxidative agent), with free radicals (ROS) and lipid peroxidation (TBARS) being reduced up to 69% and 62% respectively. The reduction of antioxidant enzymes by TERT was also significantly attenuated up to 60% (SOD), 82% (Catalase), and Glutathione enzymes (62-65% for peroxidase and reductase; fully preventing any reduction in Glutathione S-transferase). These antioxidant effects are thought to underlie results achieved with 50mg/kg water extract of Arjuna for 7 days prior to CCL4 induced hepatotoxicity, where Arjuna significantly prevented the rise in GPT (dose dependent reductions up to 50mg/kg, no added benefit at 100mg/kg), normalized ALP, and increased hepatic levels of antioxidant levels either to control levels (Catalase and Glutathione S-Transferase) or above control (SOD), a potency similar to Vitamin C at the same oral doses.
250-500mg/kg of a hydroalcoholic extract of Arjuna bark (not an oral study, but the equivalent injected into perfused kidneys) appears to reduce oxidation and concomitantly increase antioxidant enzymes (Catalase and Glutathione). A preservation of anti-oxidant enzymes in response to CCL4 is observed to be of similar potency to Vitamin C and has noted protective effects in the kidneys of Alloxan-induced diabetic rats at oral doses of 250-500mg/kg of the water extract.
Molecules that are found in Arjuna that have been noted to exert protective effects on kidney cells include Casuarinin, a tannin structure, with more potency than the water soluble form of Vitamin E known as Trolox.
In vitro, Arjuna appears to be able to reduce formation rates of calcium-based kidney stones (calcium oxalate and calcium phosphate tested) with the butanol extract being most effective.
One study using arsenic-induced testicular damage in rats noted that 4 days pretreatment with isolated Arjunolic acid can prevent oxidative testicular damange and histological changes in response to arsenic. This study noted that, in vitro, the antioxidant potential of Arjunolic Acid peaked at a concentrated of 0.4mg/mL and this appeared to correlated with an oral intake of 20mg/kg (as 50mg/kg did not confer additional protective benefits) and that the overall protective benefit was near absolute, and sligtly less effective than 100mg/kg Vitamin C.
Arjuna, particular Arjunic and Arjunolic acids, possesses anti-oxidative properties directly and in a DPPH assay (in vitro assay of antioxidative potential) has more potency than Vitamin C or at least comparable at the same concentrations. This is thought to underlie various protective effects of Arjuna in response to compounds with toxic effects mediated by oxidation such as Adriamycin cadmium, and arsenic. Despite the aforementioned study showing more potency from Arjunolic relative to Vitamin C, studies that compare the two in living systems either note similar protectiv effects or more from Vitamin C (although this latter study used a much higher dose of Vitamin C relative to Arjunic Acid).
Arjunic and Arjunolic acid appear to have direct anti-oxidative potential and sequester free radicals; the potency of it appears to be similar to Vitamin C (a few studies suggest more or less, but for the most part is similar)
Arjuna bark extracts have been found to exert antigenotoxic (protective) properties in response to 4-nitroquinoline-N-oxide, 2-aminofluorene, 4-nitro-o-phenylenediamine, and Adriamycin, with the bioactives appearing to be concentrated in the acetone and methanolic extracts.
Compounds in the ethanolic/acetone extracts appear to protect the DNA from damage induced by mutagens; the bioactives are currently unknown, and this does not appear to occur with the water extract (which is used for cardiovascular health)
Oddly, a bacteria that has been noted to produce Taxol (Paclitaxel; chemotherapeutic) has been noted to occur on Arjuna bark; this is differnt from the bacteria has been previously found on Taxus brevifolia that herb which has a bacterial strain synthesizing Taxol.
Possesses a novel bacteria on the tree which produces the chemotherapeutic Taxol; practical significance unknown, and Arjuna extracts may not have a Taxol content regardless
In response to incubation with an Ehrlich ascites carcinoma (an undifferentiated carcinoma tumor used in research with high differentiation rates and easy transplantation following injections ) noted that 9 days of Arjuna leaf methanolic extract was able to reduce tumor size (43-67%; nonsignificantly less effective than 20mg/kg 5-fluorouracil) and survival time was extended 43.9% and 87.9% at 100mg/kg and 200mg/kg, with the higher dose not being significantly different than the active control of 5-fluorouracil at 20mg/kg. Arjuna leaf extract appeared to have similar effects on white and red blood cell counts as did 5-fluorouracil.
In vitro, the main bioactive Arjunic Acid at 100mcg concentration appears to induce up to 70% cytotoxicity in these cells and has been noted to influence another cancer cell line (Dalton's lymphoma), with the latter cell line showing up to 90% cytotoxicity with 200mcg/mL of an ethanolic extract of Arjuna Bark and later being confirmed to reduce DLA tumor cell count in a mouse model by 45% and increase lifespan by 60.42% (50mg/kg) and 60% reduce cell count with a 87.50% increase in lifespan (100mg/kg) following oral ingestion of Arjuna bark extract for 10 days, although the higher dose appears to reduce white blood cell count (50mg/kg not affecting WBCs), 2-10mg/kg were also effective on both parameters, but to a lesser degree. One other study using 3-4g/kg Arjuna water extract in mice did not specifically measure tumor size, but in a Dalton's Lymphoma cell line the alterations of anti-oxidant enzymes (Catalase, SOD, Glutatione S-Transferase) effectively normalized the reductions, and reduced LDH levels in serum by 71% (relative to tumor control) at the higher dose.
In a rodent model of DMBA-induced oral carcinogenesis, the water extract of the bark of Arjuna at 500mg/kg appeared to suppress the development of tumors from 100% in control to 30% and reduced average tumor size to 33% of control. This was associated with less adverse histological changes (keratosis, hyperplasia and dysplasia) and improvments in oxidative biomarkers such as TBARS, and the protective effects were thought to be related to anti-oxidant mechanisms.
One study has suggested that Casuarinin may induce apoptosis in human non-small cell lung cancer cells (A549) related to apoptosis at G0/G1 from inducing p21/WAF1 via p53.
In isolated HepG2 carcinoma cells, 60-100mg/mL of the ethanolic extract of Arjuna Bark is able to induce an apoptotic morphology unto cells in a concentration dependent manner associated with induction of p53.
In research models of Hepatocellular Carcinoma induced by N-nitrosodiethylamine (one study duplicated in Medline) the ethanolic extract of Arjuna bark at 400mg/kg for 28 days was able to normalize TBARS (indicative of lipid peroxidation) in the liver but not serum of animals bearing N-nitrosodiethylamine tumors; this study did not measure size of tumors per se, but suggested this to be a protective effect.
An acute oral toxicity test in rats failed to find any toxicity with up to 2000mg/kg of an ethanolic extract from Arjuna. This lack of harm at the level of 2000mg/kg has been noted elsewhere in rats using bark extracts, although one study using a leaf extract noted that an LD50 occurred at 900mg/kg, suggesting higher toxicity associated with leaf based supplements; another Medline entry, which appears to be another publication of the same trial (same authors, sourcing, and introduction) also notes this 900mg/kg LD50.
- Raj CD, et al. Terminalia arjuna's antioxidant effect in isolated perfused kidney. Res Pharm Sci. (2012)
- Dwivedi S. Terminalia arjuna Wight & Arn.--a useful drug for cardiovascular disorders. J Ethnopharmacol. (2007)
- Mahmood ZA, et al. Herbal treatment for cardiovascular disease the evidence based therapy. Pak J Pharm Sci. (2010)
- Maulik SK, Katiyar CK. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. Curr Pharm Biotechnol. (2010)
- Miller AL. Botanical influences on cardiovascular disease. Altern Med Rev. (1998)
- Scassellati-Sforzolini G, et al. Antigenotoxic properties of Terminalia arjuna bark extracts. J Environ Pathol Toxicol Oncol. (1999)
- Verma SC, et al. Microwave extraction and rapid isolation of arjunic acid from Terminalia arjuna (Roxb. ex DC.) stem bark and quantification of arjunic acid and arjunolic acid using HPLC-PDA technique. J Sep Sci. (2012)
- Sarwat M, Das S, Srivastava PS. Estimation of genetic diversity and evaluation of relatedness through molecular markers among medicinally important trees: Terminalia arjuna, T. chebula and T. bellerica. Mol Biol Rep. (2011)
- Biswas M, et al. Antitumour activity of Terminalia arjuna leaf against Ehrlich ascites carcinoma in mice. Nat Prod Res. (2012)
- [No authors listed. Terminalia arjuna. Altern Med Rev. (1999)
- The chemistry of extractives from hardwoods. Part XVIII. The constitution of arjunolic acid, a triterpene from Terminalia arjuna.
- Saxena M, et al. Cytotoxic agents from Terminalia arjuna. Planta Med. (2007)
- Singh DV, et al. Quantitative determination of oleane derivatives in Terminalia arjuna by high performance thin layer chromatography. Phytochem Anal. (2002)
- Wang W, et al. 18,19-secooleanane type triterpene glycosyl esters from the bark of Terminalia arjuna. Planta Med. (2010)
- Upadhyay RK, et al. Triterpene glycoside from Terminalia arjuna. J Asian Nat Prod Res. (2001)
- Wang W, et al. Triterpenoids from two Terminalia species. Planta Med. (2010)
- Ali A, et al. A novel naphthanol glycoside from Terminalia arjuna with antioxidant and nitric oxide inhibitory activities. Pharmazie. (2003)
- Alam MS, et al. Two new bioactive oleanane triterpene glycosides from Terminalia arjuna. Nat Prod Res. (2008)
- Ali A, et al. Terminoside A, a new triterpene glycoside from the bark of Terminalia arjuna inhibits nitric oxide production in murine macrophages. J Asian Nat Prod Res. (2003)
- Singh B, et al. A new triterpene glycoside from Terminalia arjuna. Planta Med. (1995)
- Dwivedi S, Aggarwal A. Indigenous drugs in ischemic heart disease in patients with diabetes. J Altern Complement Med. (2009)
- Yadav RN, Rathore K. A new cardenolide from the roots of Terminalia arjuna. Fitoterapia. (2001)
- Yadava RN, Rathore K. A new cardenolide from the seeds of Terminalia arjuna (W&A). J Asian Nat Prod Res. (2000)
- Wang W, et al. Ursane triterpenoids from the bark of Terminalia arjuna. Fitoterapia. (2010)
- Oberoi L, et al. The aqueous extract, not organic extracts, of Terminalia arjuna bark exerts cardiotonic effect on adult ventricular myocytes. Phytomedicine. (2011)
- Kuo PL, et al. Casuarinin from the bark of Terminalia arjuna induces apoptosis and cell cycle arrest in human breast adenocarcinoma MCF-7 cells. Planta Med. (2005)
- Kandil FE, Nassar MI. A tannin anti-cancer promotor from Terminalia arjuna. Phytochemistry. (1998)
- Avula B, et al. Simultaneous Determination and Characterization of Tannins and Triterpene Saponins from the Fruits of Various Species of Terminalia and Phyllantus emblica Using a UHPLC-UV-MS Method: Application to Triphala. Planta Med. (2013)
- Khaliq F, et al. Terminalia arjuna Improves Cardiovascular Autonomic Neuropathy in Streptozotocin-Induced Diabetic Rats. Cardiovasc Toxicol. (2013)
- Dall'Ago P, et al. Baroreflex and chemoreflex dysfunction in streptozotocin-diabetic rats. Braz J Med Biol Res. (1997)
- Parveen A, et al. Terminalia arjuna enhances baroreflex sensitivity and myocardial function in isoproterenol-induced chronic heart failure rats. J Cardiovasc Pharmacol Ther. (2012)
- Parveen A, et al. Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. Cardiovasc Toxicol. (2011)
- Kumar S, et al. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). J Pharm Pharmacol. (2009)
- Sinha M, Manna P, Sil PC. Terminalia arjuna protects mouse hearts against sodium fluoride-induced oxidative stress. J Med Food. (2008)
- Singh G, et al. Protective effects of Terminalia arjuna against Doxorubicin-induced cardiotoxicity. J Ethnopharmacol. (2008)
- Karthikeyan K, et al. Cardioprotective effect of the alcoholic extract of Terminalia arjuna bark in an in vivo model of myocardial ischemic reperfusion injury. Life Sci. (2003)
- Gauthaman K, et al. Terminalia arjuna (Roxb.) protects rabbit heart against ischemic-reperfusion injury: role of antioxidant enzymes and heat shock protein. J Ethnopharmacol. (2005)
- Manna P, Sinha M, Sil PC. Phytomedicinal activity of Terminalia arjuna against carbon tetrachloride induced cardiac oxidative stress. Pathophysiology. (2007)
- Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J. (1997)
- Lehmann KG, Francis CK, Dodge HT. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group. Ann Intern Med. (1992)
- Ischemic mitral regurgitation: mechanisms and echocardiographic classification.
- Dwivedi S, et al. Role of Terminalia arjuna in ischaemic mitral regurgitation. Int J Cardiol. (2005)
- Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol. (1995)
- Bharani A, et al. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J. (2002)
- Dwivedi S, Kumar V. Beta-thalassemia, hyperlipoproteinemia(a), and metabolic syndrome: its low-cost holistic therapy. J Altern Complement Med. (2007)
- Subramaniam S, et al. Anti-Atherogenic Activity of Ethanolic Fraction of Terminalia arjuna Bark on Hypercholesterolemic Rabbits. Evid Based Complement Alternat Med. (2011)
- Subramaniam S, et al. Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX- 407 induced hyperlipidemia. Indian J Exp Biol. (2011)
- Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol. (1993)
- Chander R, et al. Antidyslipidemic and antioxidant activities of different fractions ofTerminalia arjuna stem bark. Indian J Clin Biochem. (2004)
- Bharani A, Ahirwar LK, Jain N. Terminalia arjuna reverses impaired endothelial function in chronic smokers. Indian Heart J. (2004)
- Saha S, Verma R. Inhibitory potential of traditional herbs on α-amylase activity. Pharm Biol. (2012)
- Biswas M, et al. Antihyperglycemic activity and antioxidant role of Terminalia arjuna leaf in streptozotocin-induced diabetic rats. Pharm Biol. (2011)
- Sandhu JS, et al. Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults. Int J Ayurveda Res. (2010)
- Parmar HS, et al. Cardio-protective role of Terminalia arjuna bark extract is possibly mediated through alterations in thyroid hormones. Pharmazie. (2006)
- Watanabe H, et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun. (2003)
- Donatelli M, et al. Cardiac changes in subclinical and overt hyperthyroid women: retrospective study. Int J Cardiol. (2003)
- Devi RS, et al. Effect of methanolic extract of Terminalia arjuna against Helicobacter pylori 26695 lipopolysaccharide-induced gastric ulcer in rats. J Pharm Pharmacol. (2008)
- Devi RS, et al. Ulcer protective effect of Terminalia arjuna on gastric mucosal defensive mechanism in experimental rats. Phytother Res. (2007)
- Devi RS, et al. Gastroprotective effect of Terminalia arjuna bark on diclofenac sodium induced gastric ulcer. Chem Biol Interact. (2007)
- Aneja KR, Sharma C, Joshi R. Antimicrobial activity of Terminalia arjuna Wight & Arn.: an ethnomedicinal plant against pathogens causing ear infection. Braz J Otorhinolaryngol. (2012)
- Shivananjappa MM, Mhasavade D, Joshi MK. Aqueous extract of Terminalia arjuna attenuates tert-butyl hydroperoxide-induced oxidative stress in HepG2 cell model. Cell Biochem Funct. (2012)
- Manna P, Sinha M, Sil PC. Aqueous extract of Terminalia arjuna prevents carbon tetrachloride induced hepatic and renal disorders. BMC Complement Altern Med. (2006)
- Ragavan B, Krishnakumari S. Effect of terminalia arjuna stem bark extract on the activities of marker enzymes in alloxan induced diabetic rats. Anc Sci Life. (2005)
- Raghavan B, Kumari SK. Effect of Terminalia arjuna stem bark on antioxidant status in liver and kidney of alloxan diabetic rats. Indian J Physiol Pharmacol. (2006)
- Chen CH, et al. Casuarinin protects cultured MDCK cells from hydrogen peroxide-induced oxidative stress and DNA oxidative damage. Planta Med. (2004)
- Chaudhary A, Singla SK, Tandon C. In vitro Evaluation of Terminalia arjuna on Calcium Phosphate and Calcium Oxalate Crystallization. Indian J Pharm Sci. (2010)
- Manna P, Sinha M, Sil PC. Protection of arsenic-induced testicular oxidative stress by arjunolic acid. Redox Rep. (2008)
- Pawar RS, Bhutani KK. Effect of oleanane triterpenoids from Terminalia arjuna--a cardioprotective drug on the process of respiratory oxyburst. Phytomedicine. (2005)
- Sun FY, et al. Arjunic acid, a strong free radical scavenger from Terminalia arjuna. Am J Chin Med. (2008)
- Reddy TK, et al. Effect of Terminalia arjuna extract on adriamycin-induced DNA damage. Phytother Res. (2008)
- Pal S, et al. Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro. Toxicology. (2011)
- Manna P, et al. Arjunolic acid, a triterpenoid saponin, ameliorates arsenic-induced cyto-toxicity in hepatocytes. Chem Biol Interact. (2007)
- Kaur K, et al. Antimutagenic activities of acetone and methanol fractions of Terminalia arjuna. Food Chem Toxicol. (2002)
- Gangadevi V, Muthumary J. A novel endophytic Taxol-producing fungus Chaetomella raphigera isolated from a medicinal plant, Terminalia arjuna. Appl Biochem Biotechnol. (2009)
- Gangadevi V, Muthumary J. Taxol production by Pestalotiopsis terminaliae, an endophytic fungus of Terminalia arjuna (arjun tree). Biotechnol Appl Biochem. (2009)
- Ehrlich ascites carcinoma.
- Ramesh AS, et al. Isolation, characterisation and cytotoxicity study of arjunolic acid from Terminalia arjuna. Nat Prod Res. (2012)
- Ganesan R, Kamalraj P, Muthuchelian K. Protective effects of ethanolic extract residue isolated from the bark of Terminalia Arjuna against DLA tumour cells. Asian Pac J Cancer Prev. (2010)
- Verma N, Vinayak M. Effect of Terminalia arjuna on antioxidant defense system in cancer. Mol Biol Rep. (2009)
- Dhanarasu S, et al. Terminalia Arjuna (Roxb.) Modulates Circulatory Antioxidants on 7,12-dimethylbenz(a)anthracene- induced Hamster Buccal Pouch Carcinogenesis. Oman Med J. (2010)
- Kuo PL, et al. Induction of cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells by casuarinin from the bark of Terminalia arjuna Linn. Anticancer Drugs. (2005)
- Sivalokanathan S, Vijayababu MR, Balasubramanian MP. Effects of Terminalia arjuna bark extract on apoptosis of human hepatoma cell line HepG2. World J Gastroenterol. (2006)
- Sivalokanathan S, Ilayaraja M, Balasubramanian MP. Antioxidant activity of Terminalia arjuna bark extract on N-nitrosodiethylamine induced hepatocellular carcinoma in rats. Mol Cell Biochem. (2006)
- Sivalokanathan S, Ilayaraja M, Balasubramanian MP. Efficacy of Terminalia arjuna (Roxb.) on N-nitrosodiethylamine induced hepatocellular carcinoma in rats. Indian J Exp Biol. (2005)